Abstract
purpose. To characterize the presence of plasminogen activators and their
inhibitors in the corneas during the inflammatory response in
naïve and immunized mice intracorneally infected with Pseudomonas aeruginosa.
methods. RT-PCR was used to detect gene expression for plasminogen activators
and their inhibitors in naïve and immunized mice. Immunoblot
analysis, zymography, and ELISA were used to demonstrate the syntheses
of these proteins.
results. Naïve mice intracorneally infected with P.
aeruginosa showed a temporally enhanced expression of
tissue-type plasminogen activator (tPA), urokinase-type plasminogen
activator (uPA), its receptor (uPAR), and plasminogen activator
inhibitors 1 and 2 (PAI-1 and PAI-2), over a several-day holding
period. Immunized mice demonstrated a lower and shorter expression of
these factors over the same period. Expression of these factors at the
mRNA and protein levels may have been due to enzymes and inhibitors
present in inflammatory cells and in resident corneal cells.
conclusions. These results show a correlation between the overexpression of the PA
system in infected naïve mice as part of the inflammatory
response, with eventual ocular destruction. Immunized mice exhibit a
more balanced and shorter expression of the PA system, which may
contribute to the restoration of corneal clarity.
The pathogen
Pseudomonas aeruginosa is
an opportunistic bacterium that causes severe corneal infection in
humans. Many of the clinical features of the infection can be
reproduced in a variety of experimental animals.
1 2 3 4 Previous studies from our laboratory have demonstrated that corneal
clarity is not restored in naïve (susceptible) C57BL/6J mice
after infection with
P. aeruginosa strain 19660 (American
Type Culture Collection, Rockville, MD [ATCC]) and that corneal
perforation, shrinkage, or both eventually occur.
5 However, either active or passive immunization results in restoration
of corneal clarity within a few days to a few weeks, despite a similar
intensity of the initial infection in both naïve and immunized
mice.
6 7 8 Peak levels of both polymorphonuclear leukocytes
(PMNs) and bacteria are detected at approximately 5 to 7 days after
infection, along with arachidonic acid metabolites and cytokines, and
then begin to decrease.
8 9 10 11 12 An increase in macrophages
also occurs, but peaks at a later stage in the inflammatory
process.
9 13 Viable bacteria are no longer detectable in
naïve mice by quantitative plate counts at 9 to 12 days after
infection, whereas the infection is cleared sooner in immunized
mice.
8 Other studies from our laboratory indicate that the
expression of both bacterial alkaline protease and host
metalloproteinases temporally correlates with the inflammatory response
and the degree of immunity.
14 15
Resident and infiltrating cells within the cornea during infection have
the ability to synthesize many proteases and their inhibitors, which
may play a role in various physiological and ocular processes. One such
proteolytic system is the plasminogen activator (PA) cascade,
consisting of the serine proteases urokinase-type plasminogen activator
(uPA) and tissue-type plasminogen activator (tPA). Both enzymes are
found in either the single- or double-chain configuration, depending on
their degree of activation, and they can convert the zymogen
plasminogen to the active form, plasmin.
16 17 Once
activated, plasmin has the ability to cleave many extracellular matrix
(ECM) proteins such as laminin, fibronectin, and nonfibrillar
collagens, as well as to activate certain matrix metalloproteinases
(MMPs), which in concert with plasmin, can lead to stromal
destruction.
18 19 20 Concomitantly, enzymatic expressions of
tPA and uPA are putatively controlled by several serine protease
inhibitors (serpins), including plasminogen activator inhibitors
(PAI)-1 and -2. At present, the PA cascade has been implicated in
neoplasia, neuronal plasticity, and ovulation, among other
processes.
21 22 23 Of special interest to this study is that
the serpins also play a role in inflammation, angiogenesis, and wound
repair.
21 23 Consequently, the purpose of the present
study was to characterize the corneal expressions of uPA, the receptor
of uPA (uPAR), tPA, and both PAIs during infection of naïve
mice and mice immunized with
P. aeruginosa.
The pooled corneal samples were homogenized with TRIzol (1 ml;
Gibco, Grand Island, NY) in a mortar (Coors Porcelain, Golden, CO) and
incubated at room temperature for 5 minutes. Two hundred microliters
chloroform was added to the extract, and the mixture was vortexed
vigorously. The extract was centrifuged at 13,000 rpm at 4°C for 15
minutes. The aqueous phase (containing total RNA) was transferred to a
new centrifuge tube. Six hundred microliters isopropyl alcohol was
added and mixed with the aqueous phase. The mixture was incubated at
room temperature for 15 minutes and centrifuged at 13,000 rpm at 4°C
for 10 minutes. The supernatant was removed, and the total RNA
precipitate was washed once with 75% ethanol and saved (in 75%
ethanol at −20°C) for RT-PCR analysis.
The total RNA was dissolved in water treated with diethyl pyrocarbonate
(DEPC), and the concentration was measured by a spectrophotometer at
260 nm. The total RNA samples were treated with DNase I (0.2 U/μl;
Ambion, Austin, TX) to remove possible DNA contamination. All the
reagents needed for RT-PCR were purchased from Perkin Elmer (Norwalk,
CT). Five hundred nanograms extracted total RNA from each sample was
used as the standard amount for each assay. RT-PCR was performed
sequentially in the same 0.65-ml RNase-free tubes under optimized
conditions, as previously described.
13 Thirty cycles were
selected for amplification of all target genes. The following specific
primers for mouse uPA, uPAR, tPA, and PAIs were designed and prepared
based on the available information for these mouse genes (GenBank,
National Center for Biotechnology, Bethesda, MD; available in the
public domain at http://www.ncbi.nlm.nih.gov). The primers, both
forward and reverse, from 5′ to 3′ were as follows: mouse uPA: GCC CAC
AGA CCT GAT GCT AT and TAG AGC CTT CTG GCC ACA CT; mouse uPAR: AGG TGG
TGA CAA GAG GCT GT and AGC TCT GGT CCA AAG AGG TG; mouse tPA: TAC AGA
GCG ACC TGC AGA GA and AAT ACA GGG CCT GCT GAC AC; mouse PAI-1: GCT GTA
GAC GAG CTG ACA CG and ACG TCA TAC TCG AGC CCA TC; and mouse PAI-2: CAC
CAC AGG GGG ATT ATT TG and TGG GAT TTC ACC TTT GGT TT. Finally, the
amplified specific genes were revealed by electrophoresis on 1%
agarose gels. A housekeeping gene (18S rRNA) was also amplified and
used as an internal control for the comparison of all time samples.
Corneal samples were homogenized as described by Brown et
al.
24 After homogenization in 200 μl of 50 mM Tris-HCl
(pH 7.4) containing 10 mM CaCl
2 and 0.25% Triton
X-100, the samples were centrifuged at 9000 rpm at 4°C for 30
minutes. The concentrations of the total protein were measured with the
BCA protein assay.
25 Equal amounts of individual samples
(5 μg protein) were mixed with 5 μl 4× sample loading buffer
(0.125 M Tris-HCl [pH 6.8], 4% SDS, 40% glycerol, and 0.02%
bromphenol blue), containing 0.1% β-mercaptoethanol, and boiled for
5 minutes. The samples and a mixture of prestained molecular weight
markers (Bio-Rad, Richmond, CA) were electrophoresed on 12% SDS gels
and subsequently transferred to nitrocellulose membranes.
A fusion protein was used under reducing conditions as a marker for
PAI-2 (gift of David Ginsburg, University of Michigan, Ann
Arbor). The membranes were blocked for 30 minutes in blocking reagent
(TBS containing 0.5% Tween 20, 3% nonfat milk, and 2% bovine serum
albumin; Blotto, Santa Cruz Biotechnology, Santa Cruz, CA) and then
incubated with the following specific primary antibodies: a polyclonal
antimurine PAI-2 antibody (2.2 μg/ml, a generous gift from Dr.
Ginsburg) and a polyclonal anti-human uPAR antibody (3 μg/ml;
American Diagnostic) on a rocker at room temperature for 2
hours. The antibody to human uPAR also recognizes mouse uPAR. Parallel
immunoblots without primary antibody treatment were processed as
negative controls. Afterward, the blots were incubated with secondary
antibodies conjugated with horseradish peroxidase (0.5 μg/ml;
Boehringer-Mannheim, Indianapolis, IN) at room temperature for 1 hour.
Finally, the blots of PAI-2 and uPAR were developed by a
chemiluminescence kit (Amersham Pharmacia Biotech, Parsippany, NJ) and
were visualized as dark bands.